Evidence map›Paper›PMID 41384217›Full record

ArticleCureus2025

Tatton-Brown-Rahman Syndrome Due to a Novel DNMT3A Variant Presenting With Autism, Attention-Deficit/Hyperactivity Disorder (ADHD), and Regression: A Saudi Case Report.

Abdulkarim O Alanazi, Enas M Aljohani, Sari Enani

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abdulkarim O AlanaziPsychiatry Department, Prince Sultan Military Medical City, Riyadh, SAU.
Enas M AljohaniPsychiatry Department, Prince Sultan Military Medical City, Riyadh, SAU.
Sari EnaniPsychiatry Department, Prince Sultan Military Medical City, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tatton-Brown-Rahman syndrome (TBRS) is a rare overgrowth/intellectual disability disorder caused by DNMT3A variants. It is characterized by tall stature, macrocephaly, and intellectual disability, with an expanding neuropsychiatric spectrum that includes autism spectrum disorder (ASD) and behavioral disturbances. We describe a young adult Saudi male with overgrowth, macrocephaly, coarse facial features, and global developmental delay. Cognitive testing confirmed mild intellectual disability with relative verbal strengths. He was diagnosed with ASD and attention-deficit/hyperactivity disorder (ADHD) and treated with methylphenidate in childhood. In early adulthood, the patient exhibited regression characterized by speech loss, decline in self-care, incontinence, and psychotic-like symptoms, alongside gastrointestinal disease. Genetic testing revealed a novel heterozygous DNMT3A missense variant (c.923G>T, p.Gly308Val) in the PWWP domain, consistent with TBRS. This case illustrates the broadened phenotype of TBRS, including ASD, ADHD, and regression, paralleling prior reports of cognitive unevenness and behavioral vulnerability. Additional findings of eczema, elevated IgE, and anemia suggest possible underrecognized systemic involvement. This case emphasizes the importance of multidisciplinary evaluation and lifelong neuropsychiatric follow-up in TBRS. As the first reported case from Saudi Arabia to our knowledge, it broadens the clinical and geographic spectrum of the disorder and highlights the association between DNMT3A variants, intellectual disability, and ASD.

Indexed as

asdautism spectrum disorderdnmt3aintellectual disabilityovergrowth syndrometatton–brown–rahman syndrometbrs

Identifiers

PMID41384217
PMCPMC12689467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.